- Home
- EDIT
EDIT
Editas Medicine Inc.
as 05-17-2024 4:00pm EST
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 493.4M | IPO Year: | 2016 |
| Target Price: | $13.90 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.91 - $11.91 | Next Earning Date: | 05-08-2024 |
| Revenue: | $69,407,000 | Revenue Growth: | 204.54% |
| Revenue Growth (this year): | -52.51% | Revenue Growth (next year): | -20.27% |
Share on Social Networks:
Stock Insider Trading Activity of Editas Medicine Inc. (EDIT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hopfield Jessica | EDIT | Director | May 13 '24 | Buy | $5.64 | 45,000 | $253,867.50 | 67,700 | SEC Form 4 |
| O'Neill Gilmore Neil | EDIT | CEO | Mar 2 '24 | Sell | $9.42 | 77,824 | $732,884.17 | 327,470 | SEC Form 4 |
| Mei Baisong | EDIT | SVP, CHIEF MEDICAL OFFICER | Mar 2 '24 | Sell | $9.42 | 20,327 | $191,425.46 | 141,543 | SEC Form 4 |
| Eaton Bruce | EDIT | EVP, CBO AND CTO | Dec 5 '23 | Sell | $10.90 | 103 | $1,122.41 | 74,791 | SEC Form 4 |
| Eaton Bruce | EDIT | EVP, CBO AND CTO | Nov 14 '23 | Sell | $8.21 | 695 | $5,705.67 | 74,894 | SEC Form 4 |
Latest Editas Medicine Inc. News
EDIT Breaking Stock News: Dive into EDIT Ticker-Specific Updates for Smart Investing
GuruFocus.com
5 days ago
Director Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (EDIT)
MT Newswires
5 days ago
Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing
GlobeNewswire
5 days ago
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
Simply Wall St.
8 days ago
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
GlobeNewswire
10 days ago
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Insider Monkey
10 days ago
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript
Motley Fool
10 days ago
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
Zacks
10 days ago